Platinum-resistant Ovarian Cancer (PROC)

Oncology

Prevalence

24.0 / 100K

Incidence

10.6 / 100K/yr

0 drugs in development·0 companies·2 clinical trials

Frequently asked questions

How many clinical trials target Platinum-resistant Ovarian Cancer (PROC)?

There are 2 clinical trials targeting Platinum-resistant Ovarian Cancer (PROC) tracked by BioSniper.

What is the prevalence of Platinum-resistant Ovarian Cancer (PROC)?

The estimated prevalence of Platinum-resistant Ovarian Cancer (PROC) is approximately 24.0 per 100,000 population.

Deep-dive into Platinum-resistant Ovarian Cancer (PROC)

Full trial data, competitive analysis, and AI-powered pipeline tracking.

Start Free Analysis
    Platinum-resistant Ovarian Cancer (PROC) — Drugs in Development & Clinical Trials | BioSniper